Clinical trials: Treatment Resistant Obsessive Compulsive Disorder
Obsessive-Compulsive Disorder
Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD
The study hypothesis is that dextro-amphetamine (d-amphetamine) will be safe and effective when used to augment treatment for Obsessive-Compulsive Disorder (OCD), and that tolerance (loss of therapeutic effect) to the medication…
- Trial name
- NCT00363298
- Testing
- dextro-amphetamine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Stanford University
Obsessive-Compulsive Disorder
Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder
Obsessive-compulsive disorder (OCD) is a common, chronic, and oftentimes disabling disorder. The only established treatments for OCD are a specific form of Cognitive Behavioral Therapy (CBT) and the Serotonin Reuptake Inhibitor…
- Trial name
- NCT00632229
- Testing
- Paliperidone
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of South Florida
Obsessive-Compulsive Disorder
Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder
This study will evaluate the safety and effectiveness of deep brain stimulation in treating people with severe and otherwise treatment-resistant obsessive-compulsive disorder.
- Trial name
- NCT00640133
- Testing
- Active DBS
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Butler Hospital
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have beneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to…
- Trial name
- NCT01813019
- Testing
- AFQ056
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Obsessive-Compulsive Disorder
Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder
Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3% of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as obsessions, and feel compelled to perform…
- Trial name
- NCT00956085
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute